Improving the success of adjuvant treatment of breast cancer and understanding the underlying causes of interpersonal variation in the response to treatment is of utmost importance for breast cancer patients’ prognosis and survival.
Multiple factors may contribute to this inter-personal variation, including baseline gut microbiome composition, diet, immune system repertoire, and interactions among all of these factors.
It has previously been established that:
- Diet can shape the microbiome both in terms of composition and function.
- The microbiome contributes to shaping the immune system. It is thus conceivable that optimizing this axis by applying a personalised nutritional regimen based on gut microbiome profiles will boost anti-tumour immune responses and improve the efficacy of therapy in breast cancer patients.
For more information on the study, visit NCT04079270 at clinicaltrials.gov
Seerave Foundation is supporting a randomized clinical trial that assesses the effects of a personalised nutritional intervention in combination to conventional therapy in breast cancer patients.
The trial will be performed as a collaborative effort between the lab of Prof. Eran Segal at Weizmann Institute and Sheba Medical Center.
The aims of the trial are:
- To develop predictive algorithms from associations between nutrition, glycemic response, gut microbiota, antibody and T cell responses.
- With the aid of these algorithms, to validate and/or further develop personalized dietary intervention (and possibly other lifestyle) protocols which will improve clinical outcomes and minimize the use of invasive medicine.
- Extend these algorithms and other protocols to other cancer types.
Please find a link to the smart phone application here: https://play.google.com/store/apps/details?id=com.weizmann
First participant finishing dietary intervention
First participant recruited